Degenerative brain diseases including ischemic stroke result in the irreversible loss of brain tissue and are mostly associated with persistent neurological deficits. Commonly, the activity of endogenous stem and progenitor cells in these diseases is not sufficient to restore tissue homeostasis and neurological function. It is broadly assumed that the plasticity of endogenous stem and progenitor cells is insufficient in the adult brain to promote tissue remodeling and enable neurological recovery. Consequently, approaches were designed to treat such diseases with stem or progenitor cells assumed to have comparable developmental potentials than the endogenous stem cells.
No takes yet. Share an insight, caveat, or question.
Giebel et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: